Rethinking Cancer Drug Development through Tumor-Agnostic Precision Medicine.

IF 33.3 1区医学 Q1 ONCOLOGY

Cancer discovery Pub Date : 2025-10-17 DOI:10.1158/2159-8290.cd-25-1457

Vivek Subbiah

引用次数: 0

Abstract

Tumor-agnostic therapies represent a revolutionary shift from century-old anatomic classifications to molecular-driven cancer treatment, in which therapeutic decisions are based on what drives the tumor rather than where it arises. This perspective calls for a transformative acceleration of tissue-agnostic drug development from today's 10 approvals to 50 to 100 within 25 years to eliminate therapeutic inequities and ensure every patient receives the right therapy based on their tumor's molecular identity, not anatomic accident.

查看原文本刊更多论文

通过肿瘤不可知论精准医学重新思考癌症药物开发。

肿瘤不可知论疗法代表了一种革命性的转变，从百年的解剖学分类到分子驱动的癌症治疗，在这种治疗中，治疗决定是基于驱动肿瘤的因素，而不是肿瘤出现的地方。这一观点要求在25年内将组织不确定药物的开发从目前的10个批准增加到50到100个，以消除治疗不公平，并确保每个患者根据其肿瘤的分子特征接受正确的治疗，而不是解剖事故。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer discovery ONCOLOGY-

CiteScore

22.90

自引率

1.40%

发文量

838

审稿时长

6-12 weeks

期刊介绍： Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.